Vanguard Group Inc Contrafect Corp Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.09 - $0.19 $18,497 - $39,050	-205,531 Reduced 32.65%	423,968 $42,000
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $168,501 - $3.29 Million	-936,118 Reduced 59.79%	629,499 $106,000
Q2 2022 Aug 12, 2022	BUY	$2.79 - $4.45 $38,276 - $61,049	13,719 Added 0.88%	1,565,617 $4.81 Million
Q1 2022 May 13, 2022	BUY	$2.26 - $3.84 $25,004 - $42,485	11,064 Added 0.72%	1,551,898 $5.66 Million
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $56,034 - $93,920	-22,686 Reduced 1.45%	1,540,834 $4.05 Million
Q3 2021 Nov 12, 2021	BUY	$3.19 - $4.43 $205,442 - $285,300	64,402 Added 4.3%	1,563,520 $6.33 Million
Q2 2021 Aug 13, 2021	BUY	$3.58 - $4.9 $5.37 Million - $7.35 Million	1,499,118 New	1,499,118 $6.6 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.